Unicycive Shares Rise After FDA Accepts Resubmitted NDA for OLC
Unicycive Therapeutics saw its stock climb after the U.S. Food and Drug Administration accepted the company's resubmitted New Drug Application for oxylanthanum carbonate (OLC). The agency classified the filing as a Class II complete response with a six-month review window and set a PDUFA target action date of June 27, 2026. Unicycive reported $41.3…